Upgrade to SI Premium - Free Trial

BMO Capital Maintains Underperform Rating on Neurocrine Bio (NBIX), "Outlook for Ingrezza Has Not Changed"

May 4, 2022 8:11 AM
BMO Capital analyst Evan David Seigerman reiterated an Underperform rating and $82.00 price target on Neurocrine Bio. (NASDAQ: NBIX), following ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments

Next Articles